Johnston SRD - Search Results

1

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.

Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Johnston SRD, et al. J Clin Oncol. 2021 Jan 1;39(1):79-89. doi: 10.1200/JCO.20.01894. Epub 2020 Aug 21. J Clin Oncol. 2021. PMID: 32822287 Clinical Trial.

2

Towards a molecular basis for tamoxifen resistance in breast cancer.

Johnston SR, Dowsett M, Smith IE. Johnston SR, et al. Ann Oncol. 1992 Jul;3(7):503-11. doi: 10.1093/oxfordjournals.annonc.a058251. Ann Oncol. 1992. PMID: 1498070 Free article. Review.

3

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Johnston SR, et al. Cancer Res. 1994 Nov 15;54(22):5875-81. Cancer Res. 1994. PMID: 7954417 Clinical Trial.

4

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

Newby JC, Johnston SR, Smith IE, Dowsett M. Newby JC, et al. Clin Cancer Res. 1997 Sep;3(9):1643-51. Clin Cancer Res. 1997. PMID: 9815855

5

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. Dowsett M, et al. Clin Cancer Res. 1995 Dec;1(12):1511-5. Clin Cancer Res. 1995. PMID: 9815951 Clinical Trial.

6

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Dowsett M, et al. Clin Cancer Res. 1999 Sep;5(9):2338-43. Clin Cancer Res. 1999. PMID: 10499602 Clinical Trial.

7

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.

Smith IE, Johnston SR, O'Brien ME, Hickish TF, de Boer RH, Norton A, Cirkel DT, Barton CM. Smith IE, et al. J Clin Oncol. 2000 Jun;18(12):2378-84. doi: 10.1200/JCO.2000.18.12.2378. J Clin Oncol. 2000. PMID: 10856097 Clinical Trial.

8

Irreversible aromatase inactivation: treatment for breast cancer.

Johnston SR. Johnston SR. Hosp Med. 2000 Sep;61(9):650-5. doi: 10.12968/hosp.2000.61.9.1424. Hosp Med. 2000. PMID: 11048608 Review.

9

Multimodality therapy in inflammatory breast cancer: is there a place for surgery?

De Boer RH, Allum WH, Ebbs SR, Gui GP, Johnston SR, Sacks NP, Walsh G, Ashley S, Smith IE. De Boer RH, et al. Ann Oncol. 2000 Sep;11(9):1147-53. doi: 10.1023/a:1008374931854. Ann Oncol. 2000. PMID: 11061610 Free article.

10

GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.

Vaughan MM, Moore J, Riches PG, Johnston SR, A'Hern RP, Hill ME, Eisen T, Ayliffe MJ, Thomas JM, Gore ME. Vaughan MM, et al. Ann Oncol. 2000 Sep;11(9):1183-9. doi: 10.1023/a:1008348005349. Ann Oncol. 2000. PMID: 11061616 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page